Amicus Therapeutics Inc (FOLD)
11.34
-0.13
(-1.13%)
USD |
NASDAQ |
Nov 04, 16:00
11.34
0.00 (0.00%)
After-Hours: 20:00
Amicus Therapeutics Enterprise Value: 3.492B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 3.492B |
| November 01, 2024 | 3.531B |
| October 31, 2024 | 3.516B |
| October 30, 2024 | 3.563B |
| October 29, 2024 | 3.537B |
| October 28, 2024 | 3.546B |
| October 25, 2024 | 3.596B |
| October 24, 2024 | 3.617B |
| October 23, 2024 | 3.510B |
| October 22, 2024 | 3.649B |
| October 21, 2024 | 3.691B |
| October 18, 2024 | 3.658B |
| October 17, 2024 | 3.679B |
| October 16, 2024 | 3.243B |
| October 15, 2024 | 3.187B |
| October 14, 2024 | 3.219B |
| October 11, 2024 | 3.243B |
| October 10, 2024 | 3.110B |
| October 09, 2024 | 3.142B |
| October 08, 2024 | 3.107B |
| October 07, 2024 | 3.160B |
| October 04, 2024 | 3.273B |
| October 03, 2024 | 3.261B |
| October 02, 2024 | 3.270B |
| October 01, 2024 | 3.291B |
| Date | Value |
|---|---|
| September 30, 2024 | 3.296B |
| September 27, 2024 | 3.305B |
| September 26, 2024 | 3.308B |
| September 25, 2024 | 3.356B |
| September 24, 2024 | 3.457B |
| September 23, 2024 | 3.457B |
| September 20, 2024 | 3.477B |
| September 19, 2024 | 3.391B |
| September 18, 2024 | 3.365B |
| September 17, 2024 | 3.451B |
| September 16, 2024 | 3.409B |
| September 13, 2024 | 3.480B |
| September 12, 2024 | 3.474B |
| September 11, 2024 | 3.471B |
| September 10, 2024 | 3.466B |
| September 09, 2024 | 3.543B |
| September 06, 2024 | 3.584B |
| September 05, 2024 | 3.596B |
| September 04, 2024 | 3.546B |
| September 03, 2024 | 3.578B |
| August 30, 2024 | 3.572B |
| August 29, 2024 | 3.480B |
| August 28, 2024 | 3.454B |
| August 27, 2024 | 3.522B |
| August 26, 2024 | 3.584B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.402B
Minimum
Mar 12 2020
6.366B
Maximum
Dec 22 2020
3.234B
Average
3.187B
Median
Jul 31 2024
Enterprise Value Benchmarks
| Tonix Pharmaceuticals Holding Corp | 7.452M |
| Alnylam Pharmaceuticals Inc | 33.06B |
| Krystal Biotech Inc | 4.349B |
| Akero Therapeutics Inc | 1.499B |
| NovaBay Pharmaceuticals Inc | 3.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.70M |
| Revenue (Quarterly) | 126.67M |
| Total Expenses (Quarterly) | 111.70M |
| EPS Diluted (Quarterly) | -0.05 |
| Gross Profit Margin (Quarterly) | 91.11% |
| Profit Margin (Quarterly) | -12.39% |
| Earnings Yield | -3.44% |
| Normalized Earnings Yield | -2.925 |